| Identification | Back Directory | [Name]
N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- | [CAS]
1263369-28-3 | [Synonyms]
CDK9-IN-2
CDK9 inhibitor 2
N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel-
N2'-(trans-4-Aminocyclohexyl)-5'-chloro-N6-[(3-fluorophenyl)methyl]-[2,4'-bipyridine]-2',6-diamine
[2,4'-Bipyridine]-2',6-diamine, N2'-(trans-4-aminocyclohexyl)-5'-chloro-N6-[(3-fluorophenyl)methyl]- | [Molecular Formula]
C23H25ClFN5 | [MDL Number]
MFCD25562908 | [MOL File]
1263369-28-3.mol | [Molecular Weight]
425.93 |
| Chemical Properties | Back Directory | [Boiling point ]
603.1±55.0 °C(Predicted) | [density ]
1.302±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (117.39 mM; Need ultrasonic) | [form ]
Powder | [pka]
10.40±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. | [in vitro]
In Vitro:CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic (PD) marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment and is further reduced after 16 hour exposure to CDK9-IN-2 (500 nM)[1]. | [References]
References:[1]. Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|